No Evidence for Evolution of Protease Inhibitor Resistance from Standard Genotyping,After Three Years of Treatment with Darunavir/Ritonavir,With or Without Nucleoside Analogues
Restricted accessResearch articleFirst published online October, 2012
No Evidence for Evolution of Protease Inhibitor Resistance from Standard Genotyping,After Three Years of Treatment with Darunavir/Ritonavir,With or Without Nucleoside Analogues
GuptaR, HillA, SawyerAet al.Emergence of drug resistance in HIV Type 1-infected patients after receipt of first-line highly active antiretroviral therapy: A systematic review of clinical trials. Clin Infect Dis, 2008; 47:712–722.
2.
The UK Collaborative Group on HIV Drug Resistance and UK CHIC Study Group. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS, 2005; 19:487–494.
3.
Von WylV, YerlyS, BoniJ, BurgisserP, KlimkaitT, BattegayMet al.Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: A comparison of different regimen types. Arch Intern Med, 2007; 167:1782–1790.
4.
BiermanWF, van AgtmaelMA, NijhuisM, DannerSA, BoucherCA. HIV monotherapy with ritonavir-boosted protease inhibitors: A systematic review. AIDS, 2009; 23:279–291.
5.
BattegayM, BucherH. Antiretroviral monotherapy: Should we abandon the principles of successful antiretroviral therapy?AIDS, 2010; 24,7:1057–1059.
6.
ArribasJ, HorbanA, GerstoftJet al.The MONET trial: Darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS, 2010; 24,2:223–230.
7.
ClumeckN, RiegerA, BanhegyiD, SchmidtW, HillA, van DelftYet al.96 week results from the MONET trial: A randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline. J Antimicrob Chemother, 2011; 66,8:1878–1885.
8.
HirschM, GunthardH, SchapiroJet al.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis, 2008; 47:266–285.
9.
Stanford University HIV Drug resistance database: A curated public database designed to represent, store, analyse different forms of data underlying HIV drug resistance. http://hivdb.stanford.edu/index.html. 2010January.
10.
PulidoF, ArribasJR, HillA, Van DelftY, MoecklinghoffC. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy. Antivir Ther, 2011; 16,1:59–65.
11.
ValentinM, DuvivierC, LambertS, FlandreP, CabieP, MolinaJet al.Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression in the MONOI-ANRS 136 trial: Results at week 96. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, February 2011[Abstr. 534].
12.
PulidoF, Perez-ValeroI, DelgadoR, ArranzA, PasquauJ, PortillaJet al.Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther, 2009; 14:195–201.
13.
MeynardJ, ButeloupV, LandmanR, BonnardP, BaillatV, CabieAet al.Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: The Kalesolo trial. J Antmicrob Chemother, 2010; 65:2436–2444.
14.
ProsperiM, MackieN, Di GiambenedettoS, ZazziM, CamachoR, FantiRet al.Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicenter cohort study. J Antimicrob Chemother, 2011; 66,8:1886–1896.
15.
McKinnonJ, DelgadoR, PulidoF, ShaoW, ArribasJ, MellorsJ. Single genome sequencing of HIV-1 gag and protease inhibitor resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy. Antivir Ther, 2011; 16,5:725–732.
